E7107
- Generic Name
- E7107
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C40H66N2O9
- CAS Number
- 630100-90-2
- Unique Ingredient Identifier
- R60DZX1E2N
- Background
E7107 has been used in trials studying the treatment of Cancer.
- Associated Conditions
- -
- Associated Therapies
- -
A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00499499
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2009-03-24
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 40
- Registration Number
- NCT00459823
- Locations
- 🇪🇸
Medical Oncology Service. Vall d'Hebron University Hospital, Barcelona, Spain
🇳🇱Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath